Premium
Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy
Author(s) -
Brown Zachary J.,
Greten Tim F.,
Heinrich Bernd
Publication year - 2019
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.30633
Subject(s) - hepatocellular carcinoma , medicine , adjuvant , immunotherapy , adjuvant therapy , immune system , oncology , immunology , cancer
Although patients undergo procedures with curative intent for early‐stage hepatocellular carcinoma (HCC), up to 70% of patients may have disease recurrence in the liver at 5 years. Thus far, no therapy has proven to be effective in the adjuvant setting. Here, we discuss the application of immune‐based therapies in the adjuvant setting for HCC, focusing on the underlying rationale for immunotherapies, which patients may benefit from an immune‐based therapy, and what type of immune therapy should be implemented.